Enzyme butyrylcholinesterase (BChE) shows increased activity in some brain regions after progression of Alzheimer’s disease and is therefore one of the therapeutic targets for symptomatic treatment of this neurodegenerative disorder. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.